Grail released updated PATHFINDER data from its large U.S. study showing improved positive predictive value for the Galleri multi‑cancer early detection blood test, strengthening the company’s regulatory and commercialization case. In participants followed more than a year, the test’s sensitivity for cancers rose to about 40% with a higher fraction detected at early stages; positive predictive value climbed to roughly 62% in the studied cohort. Company analysts and external experts hailed the accuracy gains but flagged remaining questions about implementation, downstream diagnostic workflows, and net clinical benefit in broad screening populations. As Grail prepares for regulatory filings, the new data sharpen both the argument for Galleri’s potential public‑health value and the scrutiny around false positives and health-system readiness.